Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Orkla on its divestment of Enter Fonder to Pareto
Mandate

Vinge advises Orkla on its divestment of Enter Fonder to Pareto

April 04, 2016

Vinge advises Orkla ASA on the divestment (indirectly) of its shares in Enter Fonder to Pareto AS. The transaction makes Pareto the new majority shareholder of Enter. The transaction is subject to relevant approvals from the Swedish Financial Supervisory Authority (Finansinspektionen).

Vinge’s team consists of partner in charge Peter Sundgren (M&A), partner Emma Stuart-Beck (financial regulatory), partner Odile Fallenius and counsel Maria Schultzberg (tax) and associates Oscar Rydén and Louise Nordkvist (M&A).

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026